Slide 1: Orion Half-Year Financial Report 1−6/2022
Orion Half-Year Financial Report 1−6/2022
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January−June 2022
Highlights in January−June 2022
Slide 4: Important news for Orion’s future
Important news for Orion’s future Orion • Orion’s R&D’s focus areas are cancer and pain • Orion gained rights to a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain • Acquisition of animal health company VMD • Liisa Hurme appointed President & CEO as of 1 November 2022
Slide 5: Key figures 1−6/2022
Key figures 1−6/2022 Net sales Operating profit Operating profit Cash flow from margin operating activities per share 554 153 28% 0.59 MEUR (524) MEUR (146) (28%) EUR (0.71) +6% +5% -17% Half-Year Financial Report 1−6/2022 © Orion Corporation 15 July 2022 5
Slide 6: Development of net sales in 1−6/2022 vs. 1−6/2021
Development of net sales in 1−6/2022 vs. 1−6/2021 15 2 554 10 5 -8 20 524 -14 * Nubeqa® product sales & royalty ** Proprietary Products and Specialty Products *** Animal Health, Fermion and Contract Manufacturing **** Without Nubeqa® royalties The figures in the chart are rounded, which is why the t
Slide 7: Development of operating profit in 1−6/2022 vs. 1−6/2021
Development of operating profit in 1−6/2022 vs. 1−6/2021 6 -3 20 -12 14 -18 146 153 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix change but without exchange rate effect
Slide 8: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1−6/2022 1−6/2021 1−6/2022 14% 240 28% +11% 220 200 +3% 9% 201 180 160 181 140 152 157 MEUR 120 +2% +7% 100 13% 80 -2% 60 70 72 72 77 36% 40 49 48 20 Finland Scandinavia 0 Other Europe North America RoW RoW = Rest of the World Half-Year Financial R
Slide 9: Solid development in Specialty Products and Proprietary Products
Solid development in Specialty Products and Proprietary Products 1−6/2021 1−6/2022 1−6/2022 +6% 6% 2% 300 +7% 6% 250 259 244 200 217 39% 202 MEUR 150 100 47% -16% -5% 50 Proprietary Products 37 31 38 36 2 11 0 Specialty Products Specialty Proprietary Animal Health Fermion & Other* Animal Health Prod
Slide 10: TOP 10 products in 1−6/2022
TOP 10 products in 1−6/2022 EUR million vs. 1−6/2021 1. Easyhaler® product portfolio 65 +17% 2. Stalevo®, Comtess®, Comtan® 57 +9% 3. Nubeqa® 39 +103% 4. Simdax® 24 -16% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 17 -8% 6. Divina® series 14 +20% 7. Solomet® 13 +25% 8. Burana® 12 +14% 9. dexdor
Slide 11: Proprietary Products
Proprietary Products GRION Building well-being
Slide 12: Nubeqa® driving the growth
Nubeqa® driving the growth Proprietary Products sales split 1−6/2022 75 +17% +9% 9% 65 65 30% 55 18% 56 57 +103% 45 52 -16% MEUR -25% 35 39 -44% 25 29 24 26 15 19 20 19 11% 5 11 -5 5% 27% Easyhaler® Parkinson's Nubeqa® Simdax® Dexdor® Others* portfolio franchise Parkinson's Easyhaler® Dexdor® Simdax
Slide 13: Nubeqa® sales booked by Orion showing strong growth
Nubeqa® sales* booked by Orion showing strong growth 25,0 +103% 20,0 39 15,0 MEUR 10,0 MEUR 5,0 19 0,0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 H1'21 H1'22 Royalty Product sales to Bayer * Orion’s sales to Bayer for commercial use + royalties from Bayer Half-Year Financial Report 1
Slide 14: Easyhaler® continued on a growth path
Easyhaler® continued on a growth path 40 35 41 30 34 25 MEUR 20 MEUR +21% 15 10 5 24 21 0 +12% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 2021 2022 H1'21 H1'22 Other Budesonide-formoterol Easyhaler® Half-Year Financial Report 1−6/2022 © Orion Corporation 15 July 2022 14
Slide 15: Sales of Parkinson's franchise
Sales of Parkinson's franchise +9% 40 35 30 57 52 25 MEUR 20 MEUR 15 +9% 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 H1'21 H1'22 2019 2020 2021 2022 Half-Year Financial Report 1−6/2022 © Orion Corporation 15 July 2022 15
Slide 16: Dexdor® and Simdax® - declining as expected
Dexdor® and Simdax® - declining as expected Dexdor® Simdax® 20 20 -44% -16% 15 15 20 29 MEUR MEUR 10 10 24 MEUR MEUR 5 11 5 0 0 H1'21 H1'22 H1'21 H1'22 2019 2020 2021 2022 2019 2020 2021 2022 Half-Year Financial Report 1−6/2022 © Orion Corporation 15 July 2022 16
Slide 17: Specialty Products
Specialty Products GRION Building well-being
Slide 18: Growth in all main markets
Growth in all main markets Sales split 1−6/2022 160 +3% 140 15% 120 133 137 100 17% MEUR 80 60 +6% +11% +12% 53% 40 40 40 44 39 38 34 20 15% 0 Finland Scandinavia Eastern RoW Finland Europe & Scandinavia Russia Eastern Europe & Russia 1−6/2021 1−6/2022 Rest of the World (RoW) Half-Year Financial Rep
Slide 19: Growth in both product segments
Growth in both product segments +3% Sales split 1−6/2022 200 180 190 185 160 27% 140 120 MEUR 100 +15% 80 60 69 40 60 20 0 73% Generic Self Care prescription drugs products Generic drugs Self-care products 1−6/2021 1−6/2022 Half-Year Financial Report 1−6/2022 © Orion Corporation 15 July 2022 19
Slide 20: In Finland, Orion’s reference priced prescription drugs developed clearly better than the market
In Finland, Orion’s reference priced prescription drugs developed clearly better than the market The market for reference priced The sales of Orion's reference prescription drugs in Finland* priced prescription drugs in (1−6/2022) Finland MEUR 215 (227) MEUR 53 (48) Market development Orion’s develo
Slide 21: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1−6/2022 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 1,487 million (+4%) prescription Orion market share in drugs pharmacy 180 Orion market share in 160 160 140 p
Slide 22: Research and development
Research and development
Slide 23: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III Registration ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 2 Prostate cancer (mCRPC)
Slide 24: Orion and responsibility
Orion and responsibility Building well-being
Slide 25: Corporate responsibility – targets and performance in 2021
Corporate responsibility – targets and performance in 2021 2021 CORPORATE RESPONSIBILITY FOCUS AREA TARGET PROGRESS PATIENT SAFETY AS A TOP Ensuring reliable supply of medications PRIORITY Ensuring patient safety Improving energy efficiency ACTIVE WORK FOR A BETTER Achieving carbon neutrality of own
Slide 26: Business targets and outlook
Business targets and outlook
Slide 27: Focus areas in 2022
Focus areas in 2022 Status on 30 TARGET KPIs 2022 June 2022 Increasing the sales of Significant increase in sales of Nubeqa® booked by Orion the current product portfolio Easyhaler® product portfolio sales increase by more than 5% In-licensing of new products Portfolio enhancement through product ac
Slide 28: Outlook for 2022 (published on 13 July 2022)
Outlook for 2022 (published on 13 July 2022) Orion estimates that in 2022 net sales will be Net sales clearly higher than in 2021 (in 2021 net sales were EUR 1,041 million). Operating profit is estimated to be Operating clearly higher than in 2021 profit (in 2021 operating profit was EUR 243 million
Slide 29: Key assumptions impacting the outlook
Key assumptions impacting the outlook Operating Net sales profit + Upfront + Upfront payment payment + Nubeqa® + Nubeqa® - Simdax® + VMD acquisition - dexdor® - Simdax® - Cost inflation - dexdor® - Price competition in generics - Sales & marketing expenses Half-Year Financial Report 1−6/2022 © Orion
Slide 30: Upcoming events
Upcoming events Interim Report 1-9/2022 20/10/2022 Financial Statement Release for 2022 9/2/2023 AGM planned to be held 22/3/2023 Interim Report 1-3/2023 27/4/2023 Half-Year Financial Report 17/7/2023 Interim Report 1-9/2023 26/10/2023
Slide 31: Building well-being
Building well-being GRIoN Building well-being
Slide 32: Appendix
Appendix GRIoN Building well-being
Slide 33: Net sales and operating profit by quarter (MEUR)
Net sales and operating profit by quarter (MEUR) Net sales Operating profit 350 120 300 100 250 80 200 60 150 40 100 50 20 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Half-Year Financial Report 1−6/2022 © Orion Corporation 15 July 2022 33
Slide 34: Quarterly net sales by unit (MEUR)
Quarterly net sales by unit (MEUR) Proprietary Products Specialty Products 150 150 100 100 50 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Animal Health Fermion & Contract Manufacturing 30 30 20 20 10 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2018 2019 2020 2021 2022 2018 20